1-10 of 10
Marc Ladanyi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling

Open Access
Nan Chen, Logan C. Tyler, Anh T. Le, Eric A. Welsh, Bin Fang, Andrew Elliott, Kurtis D. Davies, Thomas Danhorn, Gregory J. Riely, Marc Ladanyi, Eric B. Haura, Robert C. Doebele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 92–105.
https://doi.org/10.1158/1535-7163.MCT-23-0218
Published: 03 January 2024
View article titled, MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling
Open the PDF for MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling in another window
Includes: Supplementary data
Journal Articles

Abstract B157: Preclinical evaluation of the blood-brain barrier permeability and intracranial efficacy of the next-generation RET inhibitor Vepafestinib

Free
Igor Odintsov, Kentaro Wakayama, Tom Zhang, Satoru Iguchi, Masanori Kato, Allan JW Lui, Inna Khodos, Morana Vojnic, Claudio Giuliano, Annalisa Bonifacio, Monika A Davare, Elisa de Stanchina, Emanuela Lovati, Marc Ladanyi, Isao Miyazaki, Romel Somwar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B157.
https://doi.org/10.1158/1535-7163.TARG-23-B157
Published: 01 December 2023
View article titled, Abstract B157: Preclinical evaluation of the blood-brain barrier permeability and intracranial efficacy of the next-generation RET inhibitor Vepafestinib
Journal Articles

Abstract P201: Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusions

Free
Jan Gerlach, Igor Odintsov, Ron Schackmann, Marc Ladanyi, Jeroen Lammerts van Bueren, Romel Somwar, Cecile Geuijen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P201.
https://doi.org/10.1158/1535-7163.TARG-21-P201
Published: 01 December 2021
View article titled, Abstract P201: Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusions
Journal Articles

Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations

Free
Igor Odintsov, Renate I. Kurth, Kota Ishizawa, Lukas Delasos, Allan J.W. Lui, Inna Khodos, Connor J. Hagen, Qing Chang, Marissa S. Mattar, Morana Vojnic, Siddharth Kunte, Annalisa Bonifacio, Claudio Giuliano, Elisa De Stanchina, Emily Cheng, Emanuela Lovati, Marc Ladanyi, Romel Somwar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P233.
https://doi.org/10.1158/1535-7163.TARG-21-P233
Published: 01 December 2021
View article titled, Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations
Journal Articles

Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers

Free
Alison M Schram, Eileen M O’Reilly, Romel Somwar, Ryma Benayed, Sara Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, David Maussang, Ernesto Wasserman, Marc Ladanyi, David M Hyman, L. Andres Sirulnik, Alexander Drilon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): PR02.
https://doi.org/10.1158/1535-7163.TARG-19-PR02
Published: 01 December 2019
View article titled, Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Journal Articles

Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer

Free
Catherine B. Meador, Hailing Jin, Elisa de Stanchina, Caroline A. Nebhan, Valentina Pirazzoli, Lu Wang, Pengcheng Lu, Huy Vuong, Katherine E. Hutchinson, Peilin Jia, Xi Chen, Rosana Eisenberg, Marc Ladanyi, Katerina Politi, Zhongming Zhao, Christine M. Lovly, Darren A.E. Cross, William Pao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (2): 542–552.
https://doi.org/10.1158/1535-7163.MCT-14-0723
Published: 09 February 2015
View article titled, Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer
Open the PDF for Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

Free
Maria E. Arcila, Khedoudja Nafa, Jamie E. Chaft, Natasha Rekhtman, Christopher Lau, Boris A. Reva, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (2): 220–229.
https://doi.org/10.1158/1535-7163.MCT-12-0620
Published: 10 February 2013
View article titled, EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
Open the PDF for EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics in another window
Includes: Supplementary data
Journal Articles

Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component

Free
Paul K. Paik, Anna M. Varghese, Camelia S. Sima, Andre L. Moreira, Marc Ladanyi, Mark G. Kris, Natasha Rekhtman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2535–2540.
https://doi.org/10.1158/1535-7163.MCT-12-0163
Published: 08 November 2012
View article titled, Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component
Open the PDF for Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component in another window
Journal Articles

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling

Free
Jamie E. Chaft, Maria E. Arcila, Paul K. Paik, Christopher Lau, Gregory J. Riely, M. Catherine Pietanza, Maureen F. Zakowski, Valerie Rusch, Camelia S. Sima, Marc Ladanyi, Mark G. Kris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 485–491.
https://doi.org/10.1158/1535-7163.MCT-11-0692
Published: 08 February 2012
View article titled, Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling
Open the PDF for Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling in another window
Journal Articles

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Free
James Bean, Cameron Brennan, Jin-Yuan Shih, Gregory Riely, Agnes Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, Janos Szoke, Stephen Broderick, Marissa Balak, Wen-Cheng Chang, Chong-Jen Yu, Adi Gazdar, Harvey Pass, Valerie Rusch, William Gerald, Shiu-Feng Huang, Pan-Chyr Yang, Vincent Miller, Marc Ladanyi, Chih-Hsin Yang, William Pao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): PR-10.
Published: 01 November 2007
View article titled, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib